TORONTO, ON--(Marketwired - March 23, 2017) - On Thursday, April 13, 2017, Xtalks will host a complimentary webinar featuring Dr. Richard Ehman, Professor of Radiology, Blanche R. & Richard J. Erlanger Professor of Medical Research, Mayo Clinic; President and CEO, Resoundant, Inc. and Jonathan Riek, Vice President, Musculoskeletal and Metabolic Imaging, BioTelemetry Research (Cardiocore & VirtualScopics) as the presenters. Fatty liver disease is a progressive disease that begins with accumulation of fat in the liver. This accumulation of fat in the liver can then lead to inflammation, at which point, the disease is referred to as steatohepatitis. The inflammation can then lead to fibrosis, which, when it becomes severe enough, becomes cirrhosis and may even lead to hepatocellular carcinoma. Fatty liver disease may be caused by excessive alcohol consumption. Nonalcoholic Fatty Liver Disease (NAFLD) is caused by a variety of factors including poor diet and exercise (the western diet) and is the leading cause of chronic liver disease in children and adults in the United States. It is also an increasingly-common reason for liver transplants in the United States. Nonalcoholic Steatohepatitis or NASH is the progression of NAFLD from simple steatosis (fat in the liver) to steatohepatitis (fat, inflammation and tissue damage in the liver). Lifestyle modification and bariatric surgery may be used to treat NAFLD or NASH. Drug therapy is also in development. The current standard for determining the stage and progression of the disease is histopathology from a liver biopsy. From the biopsy, a pathologist can determine the degree of steatosis, the amount of inflammation, the degree of fibrosis, and the amount of cellular damage. These four measurements currently comprise the NASH Clinical Research Network's scoring system for the disease. There are several issues with biopsies: they are very invasive, they have a small morbidity and mortality rate, and they only sample about 0.002% of the total liver volume. Because of the risks and sampling variability associated with liver biopsies, it would be ideal to develop noninvasive ways to assess the stage and progression of the disease. One noninvasive way to assess much of the measurements obtained from a biopsy is through imaging. This webinar will discuss noninvasive ways to assess NASH using imaging, including proton density fat fraction (PDFF), T1 relaxometry, Magnetic resonance elastography (MRE) and the latest advances in MRE and how they can be used to assess inflammation. Topics include:
Proton density fat fraction (PDFF) - a magnetic resonance imaging (MRI) technique that can accurately determine the amount of fat in the liver (steatosis)
T1 relaxometry - an MRI technique that measures the amount of extracellular fluid (which is related to the amount of fibrosis and inflammation)
Magnetic resonance elastography (MRE) - a technique that builds upon MRI to determine the stiffness of the liver, which can be used to determine the degree of fibrosis
The latest advances in MRE and how they can be used to assess inflammation
Register today to discover how partnering with BioTelemetry Research's experts will optimize your liver clinical trial! For more information or to register for this free webinar visit: Assessing NASH: Discover the Non-Invasive Techniques
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit: http://xtalks.com
For information about hosting a webinar visit: http://xtalks.com/sponsorship.ashx

Upcoming Webinar Assessing NASH: Discover the Non-Invasive Techniques

TORONTO, ON--(Marketwired - October 24, 2016) - Join industry expert Svetlana Kolchinsky, Direction of Project Operations at BioTelemetry Research (Cardiocore & VirtualScopics) on Thursday, November 3, 2016 at 11am EDT (3pm GMT/UK), as she outlines what it takes to manage multi-protocol programs and deliver consistent results. Multi-protocol programs: Are you prepared to take on the challenge of complex data acquisition parameters? Every project has a unique set of requirements that needs to be reviewed and approached carefully for successful and timely execution. For example, the study needs properly equipped clinical sites, trained technicians, experienced readers to accurately analyze the incoming data, and a proficient team ready to lead the way. A comprehensive core lab, which can efficiently execute these tasks and meet study milestones, can be a clinical lead's greatest asset. To a team of project managers at BioTelemetry Research, this is an exciting task of orchestrating a set of steps that leads to a cascade of events, which results in a symphony of data that brings joy to our customers and becomes part of a much greater production. During the webinar Kolchinsky will share operational best practices, how to successfully reduce risks, cost savings, and the benefits of partnering with a core lab, which include:
Next level planning for risk management and project/program oversight
Successful project delivery through communication and early project preparation
Key challenges and lessons learned from real life program management
Register today to discover how partnering with BioTelemetry Research ensures consistent and experienced program managers with extensive knowledge, that leads to a successful study execution. For more information or to register for this complimentary event, visit: Managing Multi-Protocol Programs & Building Efficient Partnerships
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc. ) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit: http://xtalks.com
For information about hosting a webinar visit: http://xtalks.com/sponsorship.ashx

Managing Multi-Protocol Programs & Building Efficient Partnerships, New Webinar Hosted by Xtalks

Announces Major Advancements in Research Services
Acquires RadCore Lab, LLC
June 05, 2014 12:19
| Source: BioTelemetry, Inc.
MALVERN, Pa., June 5, 2014 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (Nasdaq: BEAT ), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that Cardiocore, its research services subsidiary, acquired the assets of RadCore Lab, LLC ("RadCore"), an imaging core lab serving the biopharmaceutical and medical device research market. This acquisition broadens the Company's cardiac imaging offerings and adds new oncology, musculoskeletal and neurological imaging capabilities, supported by a state-of-the-art, cloud-based analysis platform. While this acquisition provides growth potential, it is not expected to have a material impact on the Company's 2014 results of operation. Joseph H. Capper, BioTelemetry's President and Chief Executive Officer, commented, "2014 is a pivotal year for Cardiocore. As mentioned in the past, adding adjacent service lines to our Research Services business and building a stronger presence in Europe are critical steps in assuring the long-term success of this important division. As such, the acquisition of RadCore is a key milestone in this endeavor. As clinical trial sponsors continue to streamline their outsourcing processes, an integrated cardiac and imaging testing platform will deliver much greater value in terms of speed and efficiency. We are also making excellent progress with our European initiative and will soon be opening a new location in Brussels to provide better logistical and site-level support. "The completion of these strategic imperatives, coupled with the recent awarding of the two largest studies in our history, has laid the groundwork for a record 2015 for Research Services. I congratulate the Cardiocore team, and I am confident they will continue to build on this momentum. "
Scott L. Satin, Cardiocore's President and General Manager added, "We are excited about these advancements and attribute this recent momentum to our full integration within BioTelemetry. As part of the world's largest cardiac data infrastructure, we are able to deliver unparalleled levels of quality, efficiency, speed and specialization to pharmaceutical developers and clinical research organizations. "
About Cardiocore
Cardiocore, LLC, a subsidiary of BioTelemetry, Inc., offers a full range of centralized clinical trial testing modalities for both safety and endpoint evaluation, including Electrocardiography (ECG), Holter Monitoring, Trans-telephonic Monitoring (TTM), Mobile Cardiac Telemetry (MCOT), Echocardiography (ECHO), Multi-gated Acquisition Scanning (MUGA), Angiography, and Blood Pressure Monitoring (ABPM/BP). More information about Cardiocore's services can be found at www.cardiocore.com . Investor information on BioTelemetry can be found at www.biotelinc.com . About RadCore Lab
RadCore Lab, LLC is an imaging core lab serving the biopharmaceutical and medical device industries. RadCore provides a full range of imaging services in a clinical research setting including, X-Ray Radiography (X-RAY), Dual Energy X-Ray Absorptiometry (DEXA), Breast Imaging (Mammo, U/S, MRI), Computerized Tomography (CT), Magnetic Resonance Imaging (MRI), Diagnostic Ultrasound (U/S), Vascular Ultrasound (U/S), and general Nuclear Medicine imaging such as Single-photon emission computed tomography (SPECT) and Positron Emission Tomography (PET). BioTelemetry's Cautionary Statement Regarding Forward-Looking Statements
This document includes certain forward-looking statements within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our expectations regarding the success of the RadCore transaction together with related research services advancements and related effect on the Company's operations. These statements may be identified by words such as "expect," "anticipate," "estimate," "intend," "plan," "believe," "promises" and other words and terms of similar meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of these expectations, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, effects of changes in health care legislation, effectiveness of our cost savings initiatives, relationships with our government and commercial payors, changes to insurance coverage and reimbursement levels for our products, the success of our sales and marketing initiatives, our ability to attract and retain talented executive management and sales personnel, our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business, the commercialization of new products, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development, changes in governmental regulations and legislation, the continued consolidation of payors, acceptance of our new products and services, patent protection, adverse regulatory action, litigation success, our ability to successfully create a new holding company structure and to anticipate the benefits of such structure. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our latest periodic reports on Form 10-K and 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. BioTelemetry, Inc.Heather C. GetzInvestor Relations800-908-7103
Related Articles


BioTelemetry, Inc. Announces Major Advancements in Research Services

Tiba Medical is a medical device company. It had developed the Ambulo 2400.Tiba Medical - Ambulatory Blood Pressure Monitoring Systems

Tiba Medical

June 14 , 2010 -- Washington , DC -- Cardiocore , a premier cardiac core lab , and Tiba Medical , a leading blood pressure monitoring technology provider , announced today their alliance delivering advanced blood pressure monitoring solutions for both cardiac safety and efficacy clinical trials .

Cardiocore & Tiba Medical Form Strategic Alliance Delivering Advanced Blood Pressure Monitoring Solutions in Clinical Trials.

cardioCORE

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired

cardioCORE provides centralized cardiac testing services to the pharmaceutical industry. Services include centralized electrocardiography (ECG), Holter monitoring, ambulatory blood pressure monitoring (ABPM), echocardiography (ECHO), multigated acquisition scans (MUGA), protocol development, and statistical analysis. The Company is experienced in cardiac safety and efficacy testing in Phase I-IV and Thorough QT clinical trials. These services are supported by the company's advanced data management system featuring the HolterGateway and CardioPortal.In August 2012, cardioCORE was acquired by CardioNet. The valuation of cardioCORE was undisclosed. Other terms of the deal were not released.

Name	Thomas Cooper
Firm
Work History
Other Seats	cardioCORE

Name	Title	Status
Jennifer Cotteleer	Chief Executive Officer	Current
Lawrence Satin	Chief Medical Officer	Current
Karen Shoemaker	Controller	Current

Name	Jennifer Cotteleer	Lawrence Satin	Karen Shoemaker
Work History
Title	Chief Executive Officer	Chief Medical Officer	Controller
Status	Current	Current	Current

Wells Fargo Success Story

3M Success Story

Platform Overview

cardioCORE

Executives

Board of Directors

cardioCORE Board of Director

cardioCORE Management Team

3 Team Members

Discover the right solution for your team